Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study

Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study

Abstract Background and Aims There are two types of serum uric acid‐lowering agents, the xanthine oxidoreductase (XO) inhibitor and non‐XO inhibitor. We investigated whether febuxostat, XO inhibitor, could produce more favorable effects on coronary endothelial function (CEF) and renal function than...

Full description

Bibliographic Details
Main Authors: Masami Nishino, Yasuyuki Egami, Hitoshi Nakamura, Kohei Ukita, Akito Kawamura, Yutaka Matsuhiro, Koji Yasumoto, Masaki Tsuda, Akihiro Tanaka, Naotaka Okamoto, Yasuharu Matsunaga‐Lee, Masamichi Yano, Ryu Shutta, Jun Tanouchi
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:Health Science Reports
Subjects:
coronary artery disease
endothelial function
febuxostat
renal function
uric acid
Online Access:https://doi.org/10.1002/hsr2.563

Internet

https://doi.org/10.1002/hsr2.563

Similar Items